Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Elusys Therapeutics

This article was originally published in Start Up

Executive Summary

The core technology on which EluSys Therapeutics is based is a bispecific antibody technology with broad potential to bind to and clear toxins, auto-antibodies, and pathogens. That technology, called the HP System, is based on the mechanism of immune adherence. In response to a foreign substance (an antigen) entering the bloodstream, the immune system produces antibodies that bind the antigen, forming an immune complex, which in turn activates the complement system. A complement protein attaches to the immune complex and binds to the CR1 receptor of the complement system, which is found on all red blood cells (RBCs). The bound immune complex is then transported to the liver, where it is stripped off the RBC and destroyed by macrophages. Taylor's invention uses a heteropolymer-an antibody specific for both the CR1 receptor and the target antigen-to clear the target antigen without having to activate the complement system, which improves the efficiency of the clearance process.

You may also be interested in...



Where Are They Now?

In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.

Where Are They Now?

In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.

Novel Anti-Infectives

The introduction of new anti-infective drugs has not kept pace with the ability of bacteria to resist and render ineffective just about all antibiotics developed since the late 1920's. Influenza, hepatitis, pneumonia, meningitis, AIDS, tuberculosis and plenty of other infections are killing people, and not just in third world countries. In the US, infection is the third leading cause of death, behind heart disease and cancer. Since the mid-90's, the seriousness of the bacterial drug resistance problem has caused pharmaceutical companies to redouble their R&D efforts. And the problem has spawned a new industry of start-ups as well. Elitra Pharmaceuticals and Arrow Therapeutics hope to add to the anti-infective armamentarium with drugs that attack targets necessary for bacterial growth and survival. EluSys Therapeutics has an immunological approach, taking advantage of bispecific antibodies to clear toxins and pathogens from the bloodstream. Paratek Pharmaceuticals has taken a different approach. It's attacking the mechanism of resistance directly.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC090175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel